Cubist Systematic Strategies LLC Has $973,000 Holdings in Health Catalyst, Inc. (NASDAQ:HCAT)

Cubist Systematic Strategies LLC raised its holdings in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 34.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 137,670 shares of the company’s stock after purchasing an additional 35,584 shares during the period. Cubist Systematic Strategies LLC’s holdings in Health Catalyst were worth $973,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new stake in shares of Health Catalyst in the 4th quarter valued at approximately $29,000. Aquatic Capital Management LLC acquired a new stake in shares of Health Catalyst in the 4th quarter valued at approximately $63,000. Stoneridge Investment Partners LLC acquired a new stake in shares of Health Catalyst in the 4th quarter valued at approximately $77,000. Martin Worley Group acquired a new stake in shares of Health Catalyst in the 4th quarter valued at approximately $78,000. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Health Catalyst in the 4th quarter valued at approximately $92,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Price Performance

NASDAQ HCAT opened at $4.18 on Thursday. The business has a 50 day simple moving average of $4.13 and a 200 day simple moving average of $5.86. Health Catalyst, Inc. has a 52-week low of $3.56 and a 52-week high of $9.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The stock has a market cap of $293.48 million, a price-to-earnings ratio of -3.10 and a beta of 1.56.

Insider Activity

In other news, COO Daniel Lesueur sold 16,902 shares of Health Catalyst stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total value of $76,397.04. Following the sale, the chief operating officer now directly owns 216,250 shares in the company, valued at $977,450. This trade represents a 7.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Linda Llewelyn sold 6,441 shares of Health Catalyst stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $5.43, for a total transaction of $34,974.63. Following the completion of the sale, the insider now owns 85,819 shares in the company, valued at $465,997.17. This trade represents a 6.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,588 shares of company stock worth $217,259 over the last ninety days. Insiders own 2.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. KeyCorp cut their price target on shares of Health Catalyst from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 16th. Royal Bank of Canada cut their price target on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 27th. Wells Fargo & Company lowered their target price on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, January 21st. Stifel Nicolaus increased their target price on Health Catalyst from $5.00 to $5.50 and gave the stock a “hold” rating in a research note on Thursday, May 8th. Finally, Canaccord Genuity Group lowered their target price on Health Catalyst from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Health Catalyst has an average rating of “Moderate Buy” and an average price target of $8.00.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.